Baidu
map

NEJM:帕妥珠单抗,曲妥珠单抗和多西他赛联合用药:提高HER2阳性转移性乳腺癌患者总体生存期

2015-04-02 丁宁译 MedSci原创

背景:HER2阳性的转移性乳腺癌患者,与安慰剂,曲妥珠单抗和多西他赛联合治疗相比,一线治疗帕妥珠单抗,曲妥珠单抗和多西他赛联合治疗显著提高了无进展生存期。中期分析的结果显示,帕妥珠单抗治疗显著提高了总体生存期,其平均值远远未被超越。我们报导的最终预期总体生存期的结果为平均随访的50个月。 方法:我们随机分配那些从未接受过化疗或者转移性疾病抗HER2治疗的转移性乳腺癌患者,让她们分别接受帕妥珠单抗

背景:HER2阳性的转移性乳腺癌患者,与安慰剂,曲妥珠单抗和多西他赛联合治疗相比,一线治疗帕妥珠单抗,曲妥珠单抗和多西他赛联合治疗显著提高了无进展生存期。中期分析的结果显示,帕妥珠单抗治疗显著提高了总体生存期,其平均值远远未被超越。我们报导的最终预期总体生存期的结果为平均随访的50个月。

方法:我们随机分配那些从未接受过化疗或者转移性疾病抗HER2治疗的转移性乳腺癌患者,让她们分别接受帕妥珠单抗联合用药和安慰剂联合用药治疗。次要指标是总生存期,研究者评估的无进展生存期,反应的独立评估期限和安全报告。且调整了那些中期分析之后从安慰剂治疗转到帕妥珠单抗治疗的患者的敏感分析。

结果:与安慰剂联合治疗组的40.8个月相比较(95%的置信区间[CI],35.8至48.3),帕妥珠单抗联合治疗组的平均总体生存期是56.5个月(95%的置信区间[CI],49.3未达到),(风险比支持帕妥珠单抗组,0.68;95% CI, 0.56至 0.84; P<0.001),其差异是15.7个月。这次分析没有调整帕妥珠单抗组的交叉治疗,因此较保守,而敏感性分析的结果经交叉调整后分析是一致的。研究者作为评估指标的平均无进展生存期在帕妥珠单抗组被提高了6.3个月(风险比,0.68; 95% CI, 0.58至0.80)。帕妥珠单抗延长了7.7个月的平均应答时间,将其作为独立评估指标。但多西他赛在两组给药过程中均发生了严重不利影响,需要长期心脏安全维护。

结论:在HER2阳性的转移性乳腺癌患者中,增加帕妥珠单抗至曲妥珠单抗和多西他赛中,与增加安慰剂相比,显著提高了平均总体生存期至56.5个月,且延长了以前分析显示的这种药组合功效的结果。

原始出处

Sandra M. Swain, M.D., José Baselga, M.D., Sung-Bae Kim, M.D.et.al.Pertuzumab, Trastuzumab, and Docetaxel in HER2-Positive Metastatic Breast Cancer.NEJM.2015

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (9)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1643093, encodeId=fd421643093d7, content=<a href='/topic/show?id=833e8e39dc' target=_blank style='color:#2F92EE;'>#HER2阳性转移性乳腺癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=108, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8739, encryptionId=833e8e39dc, topicName=HER2阳性转移性乳腺癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=hb2008ye, createdTime=Wed Mar 02 10:04:00 CST 2016, time=2016-03-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1648091, encodeId=206016480913d, content=<a href='/topic/show?id=d5c560226fc' target=_blank style='color:#2F92EE;'>#曲妥珠#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=60226, encryptionId=d5c560226fc, topicName=曲妥珠)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a67b23554000, createdName=linlin2320, createdTime=Sat Jan 23 07:04:00 CST 2016, time=2016-01-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1308469, encodeId=d4021308469dc, content=<a href='/topic/show?id=240f8e3234' target=_blank style='color:#2F92EE;'>#HER2阳性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8732, encryptionId=240f8e3234, topicName=HER2阳性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8409354, createdName=闆锋旦, createdTime=Sat Apr 04 07:04:00 CST 2015, time=2015-04-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1378067, encodeId=29b313e80670d, content=<a href='/topic/show?id=c29b69004f9' target=_blank style='color:#2F92EE;'>#生存期#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69004, encryptionId=c29b69004f9, topicName=生存期)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e68e415, createdName=juliusluan78, createdTime=Sat Apr 04 07:04:00 CST 2015, time=2015-04-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1386151, encodeId=1aed1386151cb, content=<a href='/topic/show?id=f08293399f9' target=_blank style='color:#2F92EE;'>#转移性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93399, encryptionId=f08293399f9, topicName=转移性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1ac22500003, createdName=1249842em09(暂无昵称), createdTime=Sat Apr 04 07:04:00 CST 2015, time=2015-04-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1514267, encodeId=8308151426eb8, content=<a href='/topic/show?id=9d7c80e14b3' target=_blank style='color:#2F92EE;'>#联合用药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=80714, encryptionId=9d7c80e14b3, topicName=联合用药)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=36f510649899, createdName=ms4964546379600229, createdTime=Sat Apr 04 07:04:00 CST 2015, time=2015-04-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1530814, encodeId=1968153081455, content=<a href='/topic/show?id=977f52e4425' target=_blank style='color:#2F92EE;'>#总体生存期#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=52744, encryptionId=977f52e4425, topicName=总体生存期)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=178512139002, createdName=swallow, createdTime=Sat Apr 04 07:04:00 CST 2015, time=2015-04-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1570951, encodeId=aaf715e095102, content=<a href='/topic/show?id=f42823e48d7' target=_blank style='color:#2F92EE;'>#乳腺癌患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23748, encryptionId=f42823e48d7, topicName=乳腺癌患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=37bc15724202, createdName=hanhaisha2013, createdTime=Sat Apr 04 07:04:00 CST 2015, time=2015-04-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=19264, encodeId=50b319264f5, content=基本确切, beContent=null, objectType=article, channel=null, level=null, likeNumber=223, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=175.8.227.**, createdTime=Thu Apr 02 22:18:00 CST 2015, time=2015-04-02, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1643093, encodeId=fd421643093d7, content=<a href='/topic/show?id=833e8e39dc' target=_blank style='color:#2F92EE;'>#HER2阳性转移性乳腺癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=108, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8739, encryptionId=833e8e39dc, topicName=HER2阳性转移性乳腺癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=hb2008ye, createdTime=Wed Mar 02 10:04:00 CST 2016, time=2016-03-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1648091, encodeId=206016480913d, content=<a href='/topic/show?id=d5c560226fc' target=_blank style='color:#2F92EE;'>#曲妥珠#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=60226, encryptionId=d5c560226fc, topicName=曲妥珠)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a67b23554000, createdName=linlin2320, createdTime=Sat Jan 23 07:04:00 CST 2016, time=2016-01-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1308469, encodeId=d4021308469dc, content=<a href='/topic/show?id=240f8e3234' target=_blank style='color:#2F92EE;'>#HER2阳性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8732, encryptionId=240f8e3234, topicName=HER2阳性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8409354, createdName=闆锋旦, createdTime=Sat Apr 04 07:04:00 CST 2015, time=2015-04-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1378067, encodeId=29b313e80670d, content=<a href='/topic/show?id=c29b69004f9' target=_blank style='color:#2F92EE;'>#生存期#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69004, encryptionId=c29b69004f9, topicName=生存期)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e68e415, createdName=juliusluan78, createdTime=Sat Apr 04 07:04:00 CST 2015, time=2015-04-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1386151, encodeId=1aed1386151cb, content=<a href='/topic/show?id=f08293399f9' target=_blank style='color:#2F92EE;'>#转移性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93399, encryptionId=f08293399f9, topicName=转移性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1ac22500003, createdName=1249842em09(暂无昵称), createdTime=Sat Apr 04 07:04:00 CST 2015, time=2015-04-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1514267, encodeId=8308151426eb8, content=<a href='/topic/show?id=9d7c80e14b3' target=_blank style='color:#2F92EE;'>#联合用药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=80714, encryptionId=9d7c80e14b3, topicName=联合用药)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=36f510649899, createdName=ms4964546379600229, createdTime=Sat Apr 04 07:04:00 CST 2015, time=2015-04-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1530814, encodeId=1968153081455, content=<a href='/topic/show?id=977f52e4425' target=_blank style='color:#2F92EE;'>#总体生存期#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=52744, encryptionId=977f52e4425, topicName=总体生存期)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=178512139002, createdName=swallow, createdTime=Sat Apr 04 07:04:00 CST 2015, time=2015-04-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1570951, encodeId=aaf715e095102, content=<a href='/topic/show?id=f42823e48d7' target=_blank style='color:#2F92EE;'>#乳腺癌患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23748, encryptionId=f42823e48d7, topicName=乳腺癌患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=37bc15724202, createdName=hanhaisha2013, createdTime=Sat Apr 04 07:04:00 CST 2015, time=2015-04-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=19264, encodeId=50b319264f5, content=基本确切, beContent=null, objectType=article, channel=null, level=null, likeNumber=223, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=175.8.227.**, createdTime=Thu Apr 02 22:18:00 CST 2015, time=2015-04-02, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1643093, encodeId=fd421643093d7, content=<a href='/topic/show?id=833e8e39dc' target=_blank style='color:#2F92EE;'>#HER2阳性转移性乳腺癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=108, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8739, encryptionId=833e8e39dc, topicName=HER2阳性转移性乳腺癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=hb2008ye, createdTime=Wed Mar 02 10:04:00 CST 2016, time=2016-03-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1648091, encodeId=206016480913d, content=<a href='/topic/show?id=d5c560226fc' target=_blank style='color:#2F92EE;'>#曲妥珠#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=60226, encryptionId=d5c560226fc, topicName=曲妥珠)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a67b23554000, createdName=linlin2320, createdTime=Sat Jan 23 07:04:00 CST 2016, time=2016-01-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1308469, encodeId=d4021308469dc, content=<a href='/topic/show?id=240f8e3234' target=_blank style='color:#2F92EE;'>#HER2阳性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8732, encryptionId=240f8e3234, topicName=HER2阳性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8409354, createdName=闆锋旦, createdTime=Sat Apr 04 07:04:00 CST 2015, time=2015-04-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1378067, encodeId=29b313e80670d, content=<a href='/topic/show?id=c29b69004f9' target=_blank style='color:#2F92EE;'>#生存期#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69004, encryptionId=c29b69004f9, topicName=生存期)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e68e415, createdName=juliusluan78, createdTime=Sat Apr 04 07:04:00 CST 2015, time=2015-04-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1386151, encodeId=1aed1386151cb, content=<a href='/topic/show?id=f08293399f9' target=_blank style='color:#2F92EE;'>#转移性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93399, encryptionId=f08293399f9, topicName=转移性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1ac22500003, createdName=1249842em09(暂无昵称), createdTime=Sat Apr 04 07:04:00 CST 2015, time=2015-04-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1514267, encodeId=8308151426eb8, content=<a href='/topic/show?id=9d7c80e14b3' target=_blank style='color:#2F92EE;'>#联合用药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=80714, encryptionId=9d7c80e14b3, topicName=联合用药)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=36f510649899, createdName=ms4964546379600229, createdTime=Sat Apr 04 07:04:00 CST 2015, time=2015-04-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1530814, encodeId=1968153081455, content=<a href='/topic/show?id=977f52e4425' target=_blank style='color:#2F92EE;'>#总体生存期#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=52744, encryptionId=977f52e4425, topicName=总体生存期)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=178512139002, createdName=swallow, createdTime=Sat Apr 04 07:04:00 CST 2015, time=2015-04-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1570951, encodeId=aaf715e095102, content=<a href='/topic/show?id=f42823e48d7' target=_blank style='color:#2F92EE;'>#乳腺癌患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23748, encryptionId=f42823e48d7, topicName=乳腺癌患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=37bc15724202, createdName=hanhaisha2013, createdTime=Sat Apr 04 07:04:00 CST 2015, time=2015-04-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=19264, encodeId=50b319264f5, content=基本确切, beContent=null, objectType=article, channel=null, level=null, likeNumber=223, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=175.8.227.**, createdTime=Thu Apr 02 22:18:00 CST 2015, time=2015-04-02, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1643093, encodeId=fd421643093d7, content=<a href='/topic/show?id=833e8e39dc' target=_blank style='color:#2F92EE;'>#HER2阳性转移性乳腺癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=108, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8739, encryptionId=833e8e39dc, topicName=HER2阳性转移性乳腺癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=hb2008ye, createdTime=Wed Mar 02 10:04:00 CST 2016, time=2016-03-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1648091, encodeId=206016480913d, content=<a href='/topic/show?id=d5c560226fc' target=_blank style='color:#2F92EE;'>#曲妥珠#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=60226, encryptionId=d5c560226fc, topicName=曲妥珠)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a67b23554000, createdName=linlin2320, createdTime=Sat Jan 23 07:04:00 CST 2016, time=2016-01-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1308469, encodeId=d4021308469dc, content=<a href='/topic/show?id=240f8e3234' target=_blank style='color:#2F92EE;'>#HER2阳性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8732, encryptionId=240f8e3234, topicName=HER2阳性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8409354, createdName=闆锋旦, createdTime=Sat Apr 04 07:04:00 CST 2015, time=2015-04-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1378067, encodeId=29b313e80670d, content=<a href='/topic/show?id=c29b69004f9' target=_blank style='color:#2F92EE;'>#生存期#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69004, encryptionId=c29b69004f9, topicName=生存期)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e68e415, createdName=juliusluan78, createdTime=Sat Apr 04 07:04:00 CST 2015, time=2015-04-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1386151, encodeId=1aed1386151cb, content=<a href='/topic/show?id=f08293399f9' target=_blank style='color:#2F92EE;'>#转移性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93399, encryptionId=f08293399f9, topicName=转移性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1ac22500003, createdName=1249842em09(暂无昵称), createdTime=Sat Apr 04 07:04:00 CST 2015, time=2015-04-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1514267, encodeId=8308151426eb8, content=<a href='/topic/show?id=9d7c80e14b3' target=_blank style='color:#2F92EE;'>#联合用药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=80714, encryptionId=9d7c80e14b3, topicName=联合用药)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=36f510649899, createdName=ms4964546379600229, createdTime=Sat Apr 04 07:04:00 CST 2015, time=2015-04-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1530814, encodeId=1968153081455, content=<a href='/topic/show?id=977f52e4425' target=_blank style='color:#2F92EE;'>#总体生存期#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=52744, encryptionId=977f52e4425, topicName=总体生存期)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=178512139002, createdName=swallow, createdTime=Sat Apr 04 07:04:00 CST 2015, time=2015-04-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1570951, encodeId=aaf715e095102, content=<a href='/topic/show?id=f42823e48d7' target=_blank style='color:#2F92EE;'>#乳腺癌患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23748, encryptionId=f42823e48d7, topicName=乳腺癌患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=37bc15724202, createdName=hanhaisha2013, createdTime=Sat Apr 04 07:04:00 CST 2015, time=2015-04-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=19264, encodeId=50b319264f5, content=基本确切, beContent=null, objectType=article, channel=null, level=null, likeNumber=223, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=175.8.227.**, createdTime=Thu Apr 02 22:18:00 CST 2015, time=2015-04-02, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1643093, encodeId=fd421643093d7, content=<a href='/topic/show?id=833e8e39dc' target=_blank style='color:#2F92EE;'>#HER2阳性转移性乳腺癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=108, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8739, encryptionId=833e8e39dc, topicName=HER2阳性转移性乳腺癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=hb2008ye, createdTime=Wed Mar 02 10:04:00 CST 2016, time=2016-03-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1648091, encodeId=206016480913d, content=<a href='/topic/show?id=d5c560226fc' target=_blank style='color:#2F92EE;'>#曲妥珠#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=60226, encryptionId=d5c560226fc, topicName=曲妥珠)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a67b23554000, createdName=linlin2320, createdTime=Sat Jan 23 07:04:00 CST 2016, time=2016-01-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1308469, encodeId=d4021308469dc, content=<a href='/topic/show?id=240f8e3234' target=_blank style='color:#2F92EE;'>#HER2阳性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8732, encryptionId=240f8e3234, topicName=HER2阳性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8409354, createdName=闆锋旦, createdTime=Sat Apr 04 07:04:00 CST 2015, time=2015-04-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1378067, encodeId=29b313e80670d, content=<a href='/topic/show?id=c29b69004f9' target=_blank style='color:#2F92EE;'>#生存期#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69004, encryptionId=c29b69004f9, topicName=生存期)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e68e415, createdName=juliusluan78, createdTime=Sat Apr 04 07:04:00 CST 2015, time=2015-04-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1386151, encodeId=1aed1386151cb, content=<a href='/topic/show?id=f08293399f9' target=_blank style='color:#2F92EE;'>#转移性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93399, encryptionId=f08293399f9, topicName=转移性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1ac22500003, createdName=1249842em09(暂无昵称), createdTime=Sat Apr 04 07:04:00 CST 2015, time=2015-04-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1514267, encodeId=8308151426eb8, content=<a href='/topic/show?id=9d7c80e14b3' target=_blank style='color:#2F92EE;'>#联合用药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=80714, encryptionId=9d7c80e14b3, topicName=联合用药)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=36f510649899, createdName=ms4964546379600229, createdTime=Sat Apr 04 07:04:00 CST 2015, time=2015-04-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1530814, encodeId=1968153081455, content=<a href='/topic/show?id=977f52e4425' target=_blank style='color:#2F92EE;'>#总体生存期#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=52744, encryptionId=977f52e4425, topicName=总体生存期)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=178512139002, createdName=swallow, createdTime=Sat Apr 04 07:04:00 CST 2015, time=2015-04-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1570951, encodeId=aaf715e095102, content=<a href='/topic/show?id=f42823e48d7' target=_blank style='color:#2F92EE;'>#乳腺癌患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23748, encryptionId=f42823e48d7, topicName=乳腺癌患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=37bc15724202, createdName=hanhaisha2013, createdTime=Sat Apr 04 07:04:00 CST 2015, time=2015-04-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=19264, encodeId=50b319264f5, content=基本确切, beContent=null, objectType=article, channel=null, level=null, likeNumber=223, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=175.8.227.**, createdTime=Thu Apr 02 22:18:00 CST 2015, time=2015-04-02, status=1, ipAttribution=)]
  6. [GetPortalCommentsPageByObjectIdResponse(id=1643093, encodeId=fd421643093d7, content=<a href='/topic/show?id=833e8e39dc' target=_blank style='color:#2F92EE;'>#HER2阳性转移性乳腺癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=108, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8739, encryptionId=833e8e39dc, topicName=HER2阳性转移性乳腺癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=hb2008ye, createdTime=Wed Mar 02 10:04:00 CST 2016, time=2016-03-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1648091, encodeId=206016480913d, content=<a href='/topic/show?id=d5c560226fc' target=_blank style='color:#2F92EE;'>#曲妥珠#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=60226, encryptionId=d5c560226fc, topicName=曲妥珠)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a67b23554000, createdName=linlin2320, createdTime=Sat Jan 23 07:04:00 CST 2016, time=2016-01-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1308469, encodeId=d4021308469dc, content=<a href='/topic/show?id=240f8e3234' target=_blank style='color:#2F92EE;'>#HER2阳性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8732, encryptionId=240f8e3234, topicName=HER2阳性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8409354, createdName=闆锋旦, createdTime=Sat Apr 04 07:04:00 CST 2015, time=2015-04-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1378067, encodeId=29b313e80670d, content=<a href='/topic/show?id=c29b69004f9' target=_blank style='color:#2F92EE;'>#生存期#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69004, encryptionId=c29b69004f9, topicName=生存期)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e68e415, createdName=juliusluan78, createdTime=Sat Apr 04 07:04:00 CST 2015, time=2015-04-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1386151, encodeId=1aed1386151cb, content=<a href='/topic/show?id=f08293399f9' target=_blank style='color:#2F92EE;'>#转移性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93399, encryptionId=f08293399f9, topicName=转移性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1ac22500003, createdName=1249842em09(暂无昵称), createdTime=Sat Apr 04 07:04:00 CST 2015, time=2015-04-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1514267, encodeId=8308151426eb8, content=<a href='/topic/show?id=9d7c80e14b3' target=_blank style='color:#2F92EE;'>#联合用药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=80714, encryptionId=9d7c80e14b3, topicName=联合用药)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=36f510649899, createdName=ms4964546379600229, createdTime=Sat Apr 04 07:04:00 CST 2015, time=2015-04-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1530814, encodeId=1968153081455, content=<a href='/topic/show?id=977f52e4425' target=_blank style='color:#2F92EE;'>#总体生存期#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=52744, encryptionId=977f52e4425, topicName=总体生存期)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=178512139002, createdName=swallow, createdTime=Sat Apr 04 07:04:00 CST 2015, time=2015-04-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1570951, encodeId=aaf715e095102, content=<a href='/topic/show?id=f42823e48d7' target=_blank style='color:#2F92EE;'>#乳腺癌患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23748, encryptionId=f42823e48d7, topicName=乳腺癌患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=37bc15724202, createdName=hanhaisha2013, createdTime=Sat Apr 04 07:04:00 CST 2015, time=2015-04-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=19264, encodeId=50b319264f5, content=基本确切, beContent=null, objectType=article, channel=null, level=null, likeNumber=223, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=175.8.227.**, createdTime=Thu Apr 02 22:18:00 CST 2015, time=2015-04-02, status=1, ipAttribution=)]
  7. [GetPortalCommentsPageByObjectIdResponse(id=1643093, encodeId=fd421643093d7, content=<a href='/topic/show?id=833e8e39dc' target=_blank style='color:#2F92EE;'>#HER2阳性转移性乳腺癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=108, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8739, encryptionId=833e8e39dc, topicName=HER2阳性转移性乳腺癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=hb2008ye, createdTime=Wed Mar 02 10:04:00 CST 2016, time=2016-03-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1648091, encodeId=206016480913d, content=<a href='/topic/show?id=d5c560226fc' target=_blank style='color:#2F92EE;'>#曲妥珠#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=60226, encryptionId=d5c560226fc, topicName=曲妥珠)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a67b23554000, createdName=linlin2320, createdTime=Sat Jan 23 07:04:00 CST 2016, time=2016-01-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1308469, encodeId=d4021308469dc, content=<a href='/topic/show?id=240f8e3234' target=_blank style='color:#2F92EE;'>#HER2阳性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8732, encryptionId=240f8e3234, topicName=HER2阳性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8409354, createdName=闆锋旦, createdTime=Sat Apr 04 07:04:00 CST 2015, time=2015-04-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1378067, encodeId=29b313e80670d, content=<a href='/topic/show?id=c29b69004f9' target=_blank style='color:#2F92EE;'>#生存期#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69004, encryptionId=c29b69004f9, topicName=生存期)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e68e415, createdName=juliusluan78, createdTime=Sat Apr 04 07:04:00 CST 2015, time=2015-04-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1386151, encodeId=1aed1386151cb, content=<a href='/topic/show?id=f08293399f9' target=_blank style='color:#2F92EE;'>#转移性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93399, encryptionId=f08293399f9, topicName=转移性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1ac22500003, createdName=1249842em09(暂无昵称), createdTime=Sat Apr 04 07:04:00 CST 2015, time=2015-04-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1514267, encodeId=8308151426eb8, content=<a href='/topic/show?id=9d7c80e14b3' target=_blank style='color:#2F92EE;'>#联合用药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=80714, encryptionId=9d7c80e14b3, topicName=联合用药)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=36f510649899, createdName=ms4964546379600229, createdTime=Sat Apr 04 07:04:00 CST 2015, time=2015-04-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1530814, encodeId=1968153081455, content=<a href='/topic/show?id=977f52e4425' target=_blank style='color:#2F92EE;'>#总体生存期#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=52744, encryptionId=977f52e4425, topicName=总体生存期)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=178512139002, createdName=swallow, createdTime=Sat Apr 04 07:04:00 CST 2015, time=2015-04-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1570951, encodeId=aaf715e095102, content=<a href='/topic/show?id=f42823e48d7' target=_blank style='color:#2F92EE;'>#乳腺癌患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23748, encryptionId=f42823e48d7, topicName=乳腺癌患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=37bc15724202, createdName=hanhaisha2013, createdTime=Sat Apr 04 07:04:00 CST 2015, time=2015-04-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=19264, encodeId=50b319264f5, content=基本确切, beContent=null, objectType=article, channel=null, level=null, likeNumber=223, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=175.8.227.**, createdTime=Thu Apr 02 22:18:00 CST 2015, time=2015-04-02, status=1, ipAttribution=)]
  8. [GetPortalCommentsPageByObjectIdResponse(id=1643093, encodeId=fd421643093d7, content=<a href='/topic/show?id=833e8e39dc' target=_blank style='color:#2F92EE;'>#HER2阳性转移性乳腺癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=108, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8739, encryptionId=833e8e39dc, topicName=HER2阳性转移性乳腺癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=hb2008ye, createdTime=Wed Mar 02 10:04:00 CST 2016, time=2016-03-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1648091, encodeId=206016480913d, content=<a href='/topic/show?id=d5c560226fc' target=_blank style='color:#2F92EE;'>#曲妥珠#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=60226, encryptionId=d5c560226fc, topicName=曲妥珠)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a67b23554000, createdName=linlin2320, createdTime=Sat Jan 23 07:04:00 CST 2016, time=2016-01-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1308469, encodeId=d4021308469dc, content=<a href='/topic/show?id=240f8e3234' target=_blank style='color:#2F92EE;'>#HER2阳性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8732, encryptionId=240f8e3234, topicName=HER2阳性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8409354, createdName=闆锋旦, createdTime=Sat Apr 04 07:04:00 CST 2015, time=2015-04-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1378067, encodeId=29b313e80670d, content=<a href='/topic/show?id=c29b69004f9' target=_blank style='color:#2F92EE;'>#生存期#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69004, encryptionId=c29b69004f9, topicName=生存期)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e68e415, createdName=juliusluan78, createdTime=Sat Apr 04 07:04:00 CST 2015, time=2015-04-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1386151, encodeId=1aed1386151cb, content=<a href='/topic/show?id=f08293399f9' target=_blank style='color:#2F92EE;'>#转移性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93399, encryptionId=f08293399f9, topicName=转移性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1ac22500003, createdName=1249842em09(暂无昵称), createdTime=Sat Apr 04 07:04:00 CST 2015, time=2015-04-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1514267, encodeId=8308151426eb8, content=<a href='/topic/show?id=9d7c80e14b3' target=_blank style='color:#2F92EE;'>#联合用药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=80714, encryptionId=9d7c80e14b3, topicName=联合用药)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=36f510649899, createdName=ms4964546379600229, createdTime=Sat Apr 04 07:04:00 CST 2015, time=2015-04-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1530814, encodeId=1968153081455, content=<a href='/topic/show?id=977f52e4425' target=_blank style='color:#2F92EE;'>#总体生存期#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=52744, encryptionId=977f52e4425, topicName=总体生存期)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=178512139002, createdName=swallow, createdTime=Sat Apr 04 07:04:00 CST 2015, time=2015-04-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1570951, encodeId=aaf715e095102, content=<a href='/topic/show?id=f42823e48d7' target=_blank style='color:#2F92EE;'>#乳腺癌患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23748, encryptionId=f42823e48d7, topicName=乳腺癌患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=37bc15724202, createdName=hanhaisha2013, createdTime=Sat Apr 04 07:04:00 CST 2015, time=2015-04-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=19264, encodeId=50b319264f5, content=基本确切, beContent=null, objectType=article, channel=null, level=null, likeNumber=223, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=175.8.227.**, createdTime=Thu Apr 02 22:18:00 CST 2015, time=2015-04-02, status=1, ipAttribution=)]
  9. [GetPortalCommentsPageByObjectIdResponse(id=1643093, encodeId=fd421643093d7, content=<a href='/topic/show?id=833e8e39dc' target=_blank style='color:#2F92EE;'>#HER2阳性转移性乳腺癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=108, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8739, encryptionId=833e8e39dc, topicName=HER2阳性转移性乳腺癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=hb2008ye, createdTime=Wed Mar 02 10:04:00 CST 2016, time=2016-03-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1648091, encodeId=206016480913d, content=<a href='/topic/show?id=d5c560226fc' target=_blank style='color:#2F92EE;'>#曲妥珠#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=60226, encryptionId=d5c560226fc, topicName=曲妥珠)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a67b23554000, createdName=linlin2320, createdTime=Sat Jan 23 07:04:00 CST 2016, time=2016-01-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1308469, encodeId=d4021308469dc, content=<a href='/topic/show?id=240f8e3234' target=_blank style='color:#2F92EE;'>#HER2阳性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8732, encryptionId=240f8e3234, topicName=HER2阳性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8409354, createdName=闆锋旦, createdTime=Sat Apr 04 07:04:00 CST 2015, time=2015-04-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1378067, encodeId=29b313e80670d, content=<a href='/topic/show?id=c29b69004f9' target=_blank style='color:#2F92EE;'>#生存期#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69004, encryptionId=c29b69004f9, topicName=生存期)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e68e415, createdName=juliusluan78, createdTime=Sat Apr 04 07:04:00 CST 2015, time=2015-04-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1386151, encodeId=1aed1386151cb, content=<a href='/topic/show?id=f08293399f9' target=_blank style='color:#2F92EE;'>#转移性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93399, encryptionId=f08293399f9, topicName=转移性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1ac22500003, createdName=1249842em09(暂无昵称), createdTime=Sat Apr 04 07:04:00 CST 2015, time=2015-04-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1514267, encodeId=8308151426eb8, content=<a href='/topic/show?id=9d7c80e14b3' target=_blank style='color:#2F92EE;'>#联合用药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=80714, encryptionId=9d7c80e14b3, topicName=联合用药)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=36f510649899, createdName=ms4964546379600229, createdTime=Sat Apr 04 07:04:00 CST 2015, time=2015-04-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1530814, encodeId=1968153081455, content=<a href='/topic/show?id=977f52e4425' target=_blank style='color:#2F92EE;'>#总体生存期#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=52744, encryptionId=977f52e4425, topicName=总体生存期)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=178512139002, createdName=swallow, createdTime=Sat Apr 04 07:04:00 CST 2015, time=2015-04-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1570951, encodeId=aaf715e095102, content=<a href='/topic/show?id=f42823e48d7' target=_blank style='color:#2F92EE;'>#乳腺癌患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23748, encryptionId=f42823e48d7, topicName=乳腺癌患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=37bc15724202, createdName=hanhaisha2013, createdTime=Sat Apr 04 07:04:00 CST 2015, time=2015-04-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=19264, encodeId=50b319264f5, content=基本确切, beContent=null, objectType=article, channel=null, level=null, likeNumber=223, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=175.8.227.**, createdTime=Thu Apr 02 22:18:00 CST 2015, time=2015-04-02, status=1, ipAttribution=)]
    2015-04-02 175.8.227.**

    基本确切

    0

相关资讯

NEJM:乳腺癌辅助化疗时戈舍瑞林有利于保护卵巢

背景:卵巢早衰是化疗常见的毒性作用,使用促性腺激素释放激素(GnRH)激动剂保护卵巢功能的研究表明,其对妊娠结果的影响喜忧参半且缺乏数据的支持。 方法:我们随机分配257名可手术的、激素受体阴性的绝经前乳腺癌患者,让她们分别接受有促性腺激素释放激素激动剂戈舍瑞林(戈舍瑞林组)的标准化疗和没有戈舍瑞林标准化疗(化疗单药组)。其主要研究指标是2年内卵巢早衰的速度,卵巢早衰的定义为停经前6个月且FSH

Sci Rep:ZNF32通过mTOR通路抑制人乳腺癌细胞的自噬

自噬(autophagy)是由 Ashford 和 Porter 在 1962 年发现细胞内有“自己吃自己”的现象后提出的,是指从粗面内质网的无核糖体附着区脱落的双层膜包裹部分胞质和细胞内需降解的细胞器、蛋白质等成分形成自噬体(autophagosome),并与溶酶体融合形成自噬溶酶体,降解其所包裹的内容物,以实现细胞本身的代谢需要和某些细胞器的更新。自噬在机体的生理和病理过程中都能见到,其所起的

NEJM:乳腺癌辅助化疗时戈舍瑞林用于保护卵巢

背景:卵巢衰竭是一种常见的化疗毒性的后果。研究使用促性腺激素释放激素(GnRH)受体激动剂保护卵巢功能显示有不同的效果,但缺失妊娠期的数据。 方法:我们随机分配了257名绝经前女性荷尔蒙-受体-阴性的女性乳腺癌患者接受标准化疗,包括GnRH受体激动剂戈舍瑞林(戈舍瑞林组)或标准化疗没有戈舍瑞林(单独化疗组)。主要研究终点是2年内卵巢衰竭的速度,卵巢衰竭定义为前6个月没有月经和在绝经后促卵泡激素(

安吉丽娜·朱莉为防癌,2年切3器官

2013年5月份,美国好莱坞女星安吉丽娜·朱莉对外宣布,通过乳腺癌易感基因检测发现,她从母亲那遗传了突变的癌症易感基因BRCA1,患乳腺癌的几率高达87%。为预防乳腺癌,朱莉进行了预防性双侧乳腺切除手术。就在当地时间本月24日她再次对外宣布,已经切除了卵巢和输卵管。两年时间内,朱莉为防癌切了三个器官。割除器官能否有效防癌? BRCA1基因,一种直接与遗传性乳腺癌有关的

BCRT:糖尿病女性更容易患进展期乳腺癌!

不少专家都对糖尿病和乳腺癌患者进行调查,发现糖尿病和乳腺癌风险有一定的关联。过去瑞典的一项病例对照研究(Cancer Causes Control. 2012 May;23(5):769-77. doi: 10.1007/s10552-012-9946-5. )表明,糖尿病和乳腺癌风险增加40%有关。即使调整了肥胖、血脂异常等混杂后,二者仍然有关联,尤其是在4年之内诊断出癌症的

Clin Cancer Res:Palbociclib 对Rb+晚期乳腺癌的II期临床研究

目的:细胞周期的G1-S检查点在乳腺癌中异常表达。Palbociclib(PD0332991)是一种口服CDK4/6抑制剂。 基于临床前/I期临床活性,我们对palbociclib用于晚期乳腺癌进行了单组II期临床试验。 实验设计:符合条件的患者经过组织学证实为转移性阳性视网膜母细胞瘤(Rb)乳腺癌以及重大疾病。Palbociclib在28天的周期里1-21日口服给药125毫克。主要指标是肿瘤反

Baidu
map
Baidu
map
Baidu
map